鼠神经生长因子联合多奈派齐治疗血管性认知障碍疗效观察  

Clinical efficacy of mouse nerve growth factor combined with donepezil in the treatment of vascular cognitive impairment

作　　者：余映丽[1] 黄晓芸[1] 陈建军[1] 王明霞[1] 官少兵[1] YU Ying-li;HUANG Xiao-yun;CHEN Jian-jun;WANG Ming-xia;GUAN Shao-bing(Department of Neurology,Dongguan Houjie Hospital,Dongguan 523960,Guangdong,CHINA)

机构地区：[1]东莞市厚街医院神经内科,广东东莞523960

出　　处：《海南医学》2021年第19期2466-2468,共3页Hainan Medical Journal

基　　金：广东省东莞市社会科技发展项目(编号:201950715023732)。

摘　　要：目的研究鼠神经生长因子联合多奈派齐治疗血管性认知障碍(VCI)的效果及对患者各项临床指标的影响。方法选择2019年1月至2021年1月东莞市厚街医院神经内科收治的60例VCI住院患者作为研究对象。根据随机数表法将患者分为研究组和对照组各30例。对照组患者采用多奈派齐治疗,研究组患者在对照组基础上联合鼠神经生长因子治疗,两组疗程均为一个月。比较两组患者的临床治疗效果,治疗前后的蒙特利尔认知评估量表(MoCA)、简明精神状态检查量表(MMSE)、阿尔茨海默病评估量表认知部分(ADAS-cog)的评分,以及血清脂蛋白相关磷脂酶A2 (Lp-PLA2)水平的变化。结果治疗前,两组患者的MoCA、MMSE、ADAS-cog评分比较差异均无统计学意义(P>0.05),治疗后,两组患者的MoCA、MMSE评分均明显升高,且研究组患者的MoCA、MMSE评分分别为(25.8±4.7)分、(26.8±4.3)分,明显高于对照组的(21.4±4.4)分、(20.7±3.8)分,ADAS-cog评分均明显下降,且研究组患者的ADAS-cog评分为(15.6±2.1)分,明显低于对照组的(17.1±2.0)分,差异均有统计学意义(P<0.05);治疗前,两组患者的Lp-PLA2水平比较差异无统计学意义(P<0.05),治疗后,两组患者的Lp-PLA2水平明显升高,且研究组患者的Lp-PLA2水平为(47.6±4.5)μg/L,明显高于对照组的(39.8±4.2)μg/L,差异均有统计学意义(P<0.05);研究组患者的治疗总有效率为90.00%,明显高于对照组的63.33%,差异有统计学意义(P<0.05)。结论鼠神经生长因子联合多奈派齐治疗VCI可有效提高患者的MoCA、MMSE评分,有利于提高患者Lp-PLA2水平,临床治疗效果显著,具有较好的临床应用价值。Objective To study the clinical efficacy of mouse nerve growth factor combined with donepezil in the treatment of patients with vascular cognitive impairment(VCI) and its influence on clinical indicators. Methods From January 2019 to January 2021, 60 VCI inpatients in the Department of Neurology, Dongguan Houjie Hospital were selected as the research objects. They were randomly divided into a study group and a control group, with 30 patients in each group.The patients in the control group were treated with donepezil, and the patients in the study group were treated with mouse nerve growth factor on the basis of the control group. The treatment course of the two groups was one month. The Montreal Cognitive Assessment Scale(MoCA), Mini Mental State Examination(MMSE), cognitive part of Alzheimer’s disease assessment scale(ADAS COG), and serum lipoprotein associated phospholipase A2(Lp-PLA2) levels of the two groups were recorded before and one month after treatment, as well as the clinical efficacy after 14 days of treatment.Results Before treatment, there was no significant difference in MoCA, MMSE, and ADAS-cog scores between the two groups(P>0.05). After treatment, MoCA and MMSE scores of the two groups were significantly increased. The scores of MoCA, MMSE, and ADAS-cog in the study group were(25.8±4.7) points and(26.8±4.3) points, respectively,which were significantly higher than(21.4 ± 4.4) points and(20.7 ± 3.8) points in the control group, and the scores of ADAS-cog in the study group were significantly lower than(15.6±2.1) points and(17.1±2.0) points in the control group,with statistically significant difference(P<0.05). Before treatment, there was no significant difference in the activity of Lp-PLA2 between the two groups(P<0.05). After treatment, the activity of Lp-PLA2 in the two groups was significantly improved, and the activity of Lp-PLA2 in the study group was(47.6 ± 4.5) μ g/L, which was significantly higher than(39.8±4.2) μg/L in the control group(P<0.05). The total effective rate of th

关 键 词：血管性认知障碍 多奈派齐 鼠神经生长因子 认知功能 脂蛋白相关磷脂酶A2 疗效 

分 类 号：R749.13[医药卫生—神经病学与精神病学]